Skip to main content
Premium Trial:

Request an Annual Quote

Inpharmatica Lands $43 million in Second Round Funding

NEW YORK, July 3 – Inpharmatica has received 31.25 million pounds ($43.9 million) in second round institutional funding, the company announced Tuesday. 

Inpharmatica, based in London, received funds from the European company Dresdner Kleinwort Capital, Abingworth Management of London, Glide Investment in The Netherlands, and Vertex Management in Singapore. Inpharmatica is now worth approximately 56 million pounds, according to the company.

The company said it plans to use this latest round of funding to establish its own drug discovery capabilities, expand its cluster computer farm, and extend its current technology platforms.

“The money raised will fund our transition from being a pure information provider into a drug discovery company,” Patrick Banks, finance director of Inpharmatica, said in a statement.

Currently, Inpharmatica’s technological scope revolves around the Biopendium and Chematica platforms, which provide subscribers with databases cataloguing protein sequence, structure, and function, as well as the ability of particular proteins to serve as drug targets. The company has collaborations with Pfizer, Genentech, and Arrow Therapeutics.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.